An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

NCT01964157 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: LDK378

Sponsor

Yonsei University